頭頸部癌におけるサブタイプ特異的依存性と薬剤脆弱性を可能にする精密治療
Joel Vaz1, Songli Zhu1, Mateo Useche2
1Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
bioRxiv : the preprint server for biology
|December 22, 2025
まとめ
この研究は、分子プロファイルに基づいて、異なる頭頸部扁平上皮癌(HNSCC)の腫瘍の状態を定義する。各サブタイプに特異的な薬剤標的を特定し、精密癌治療への道を開く。
科学分野:
- 腫瘍学
- 分子生物学
- ゲノム学
背景:
- 頭頸部扁平上皮癌(HNSCC)は、著しい分子的不均一性を示す。
- 現在のHNSCCサブタイプ分類は、直接的な治療的応用を欠いている。
研究 の 目的:
- HNSCCにおける転写的多様性と実行可能な腫瘍状態をリンクするメカニズムプラットフォームを開発すること。
- HPV陰性HNSCCのサブタイプ特異的な治療戦略を特定すること。
- EGFR阻害剤応答のための予測バイオマーカーを作成すること。
主な方法:
- 727のHNSCC腫瘍からのマルチコホートRNA-seqデータの統合解析。
- ゲノムスケールのCRISPRスクリーニングおよび薬理学的プロファイリングを利用。
- エルロチニブ応答のための機械学習ベースの転写予測因子を開発した。
主要な成果:
- 4つの異なる腫瘍生存回路を定義した:増殖性、上皮分化型、EMT様、および代謝性。
- 特定された各腫瘍回路に特異的な薬剤の負債をマッピングした。
- 高い精度(R = 0.93)でエルロチニブ応答を予測する13遺伝子シグネチャーを開発および検証した。
結論:
- HNSCCサブタイプと依存性および治療法を関連付けるフレームワークを確立した。
- HNSCC治療における精密層別化の可能性を示した。
- 治療選択をガイドするためのバイオマーカー展開のための臨床的に実行可能なアプローチを提案した。
関連する概念動画
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Dose-Response Relationship: Selectivity and Specificity
9.5K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.5K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
516
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
516


